<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR19">
 <label>19.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Conroy</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Stockett</surname>
    <given-names>DE</given-names>
   </name>
   <name>
    <surname>Walker</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Arki</surname>
    <given-names>MR</given-names>
   </name>
   <name>
    <surname>Hoch</surname>
    <given-names>U</given-names>
   </name>
   <name>
    <surname>Fox</surname>
    <given-names>JA</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples</article-title>
  <source>Cancer Chemother Pharmacol</source>
  <year>2009</year>
  <volume>64</volume>
  <fpage>723</fpage>
  <lpage>32</lpage>
  <pub-id pub-id-type="doi">10.1007/s00280-008-0921-5</pub-id>
  <?supplied-pmid 19169685?>
  <pub-id pub-id-type="pmid">19169685</pub-id>
 </element-citation>
</ref>
